Articles from Bioheng Therapeutics

Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy

Patient achieved complete remission and well-tolerated safety profile, advancing path to Phase 2

By Bioheng Therapeutics · Via GlobeNewswire · December 22, 2025

Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias

By Bioheng Therapeutics · Via GlobeNewswire · December 8, 2025

Imviva Biotech Presents Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias at the 67th American Society of Hematology Annual Meeting

Two oral presentations showcase robust efficacy and durable responses

By Bioheng Therapeutics · Via GlobeNewswire · December 8, 2025

Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting

Two oral, and five poster presentations will showcase the company’s progress in developing allogenic cell therapy candidates for multiple hematological malignancies

By Bioheng Therapeutics · Via GlobeNewswire · November 24, 2025